Ophthotech Corp.
(NASDAQ : OPHT)

( )
OPHT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Loading OPHT News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.32%73.350.9%$628.11m
CELGCelgene Corporation
-0.08%131.261.1%$437.57m
AMGNAmgen Inc.
0.79%171.391.1%$428.25m
VRTXVertex Pharmaceuticals Incorporated
-0.88%151.371.9%$388.67m
BIIBBiogen Inc.
2.14%294.081.2%$369.29m
REGNRegeneron Pharmaceuticals, Inc.
-0.85%468.542.7%$323.23m
ALXNAlexion Pharmaceuticals, Inc.
0.99%136.551.9%$224.00m
ILMNIllumina, Inc.
0.12%194.153.5%$222.63m
SRPTSarepta Therapeutics, Inc.
1.96%37.4319.8%$145.52m
INCYIncyte Corporation
-1.61%124.342.6%$135.50m
CLVSClovis Oncology, Inc.
-0.15%71.7718.0%$123.60m
KITEKite Pharma, Inc.
1.02%128.0916.1%$116.66m
TSROTESARO, Inc.
-0.89%112.9914.7%$114.54m
BMRNBioMarin Pharmaceutical Inc.
-0.01%83.074.4%$113.75m
AAgilent Technologies, Inc.
4.67%62.151.5%$112.87m

Company Profile

Ophthotech Corp. operates as a biopharmaceutical company. It focuses on discovering, developing and commercializing novel therapeutics to treat diseases of the back of the eye. It develops therapies for age-related macular degeneration. Its product candidates include Fovista Anti platelet derived growth factor Therapy, Zimura Anti-Complement and Aptamer Technology. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.